177 related articles for article (PubMed ID: 32927517)
1. [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].
Tong X; Jiang Q; Zhang P; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):907-910. PubMed ID: 32927517
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and treatment of wild-type gastrointestinal stromal tumors].
Cao H; Wang M
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):312-6. PubMed ID: 24760635
[TBL] [Abstract][Full Text] [Related]
5. Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.
Huss S; Elges S; Trautmann M; Sperveslage J; Hartmann W; Wardelmann E
Expert Rev Anticancer Ther; 2015 Jun; 15(6):623-8. PubMed ID: 25831232
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
[No Abstract] [Full Text] [Related]
7. Classification of gastrointestinal stromal tumor syndromes.
Gopie P; Mei L; Faber AC; Grossman SR; Smith SC; Boikos SA
Endocr Relat Cancer; 2018 Feb; 25(2):R49-R58. PubMed ID: 29170162
[TBL] [Abstract][Full Text] [Related]
8. "Wild type" GIST: Clinicopathological features and clinical practice.
Wada R; Arai H; Kure S; Peng WX; Naito Z
Pathol Int; 2016 Aug; 66(8):431-7. PubMed ID: 27427238
[TBL] [Abstract][Full Text] [Related]
9. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].
Kalfusová A; Kodet R
Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120
[TBL] [Abstract][Full Text] [Related]
11. Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors.
Yan W; Zhang A; Powell MJ
Chin J Cancer; 2016 Jul; 35(1):68. PubMed ID: 27443349
[TBL] [Abstract][Full Text] [Related]
12. [Wild-type gastroinestinal stromal tumors].
Djerouni M; Dumont SN
Bull Cancer; 2020 Apr; 107(4):499-505. PubMed ID: 32063345
[TBL] [Abstract][Full Text] [Related]
13. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.
Gasparotto D; Rossi S; Polano M; Tamborini E; Lorenzetto E; Sbaraglia M; Mondello A; Massani M; Lamon S; Bracci R; Mandolesi A; Frate E; Stanzial F; Agaj J; Mazzoleni G; Pilotti S; Gronchi A; Dei Tos AP; Maestro R
Clin Cancer Res; 2017 Jan; 23(1):273-282. PubMed ID: 27390349
[TBL] [Abstract][Full Text] [Related]
14. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
[TBL] [Abstract][Full Text] [Related]
15. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Nishida T; Blay JY; Hirota S; Kitagawa Y; Kang YK
Gastric Cancer; 2016 Jan; 19(1):3-14. PubMed ID: 26276366
[TBL] [Abstract][Full Text] [Related]
16. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
Nannini M; Biasco G; Astolfi A; Pantaleo MA
J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252
[TBL] [Abstract][Full Text] [Related]
17. Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST.
Astolfi A; Indio V; Nannini M; Saponara M; Schipani A; De Leo A; Altimari A; Vincenzi B; Comandini D; Grignani G; Secchiero P; Urbini M; Pantaleo MA
Front Oncol; 2020; 10():504. PubMed ID: 32391261
[No Abstract] [Full Text] [Related]
18. Molecular biomarkers for prognosis of gastrointestinal stromal tumor.
Liu X; Chu KM
Clin Transl Oncol; 2019 Feb; 21(2):145-151. PubMed ID: 30003531
[TBL] [Abstract][Full Text] [Related]
19. Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1.
Stewart DR; Corless CL; Rubin BP; Heinrich MC; Messiaen LM; Kessler LJ; Zhang PJ; Brooks DG
J Med Genet; 2007 Jan; 44(1):e61. PubMed ID: 17209131
[TBL] [Abstract][Full Text] [Related]
20. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST).
Nannini M; Urbini M; Astolfi A; Biasco G; Pantaleo MA
J Transl Med; 2017 May; 15(1):113. PubMed ID: 28535771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
